Compare LAW & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAW | BNTC |
|---|---|---|
| Founded | 2013 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 286.9M | 307.7M |
| IPO Year | 2021 | 2020 |
| Metric | LAW | BNTC |
|---|---|---|
| Price | $5.23 | $8.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $6.67 | ★ $23.29 |
| AVG Volume (30 Days) | 163.6K | ★ 178.8K |
| Earning Date | 11-04-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.58 | 6.67 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $156,849,000.00 | N/A |
| Revenue This Year | $12.02 | N/A |
| Revenue Next Year | $10.55 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 8.29 | N/A |
| 52 Week Low | $2.45 | $7.89 |
| 52 Week High | $9.11 | $16.68 |
| Indicator | LAW | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 72.87 | 42.82 |
| Support Level | $3.93 | $8.26 |
| Resistance Level | N/A | $9.29 |
| Average True Range (ATR) | 0.21 | 0.58 |
| MACD | 0.07 | 0.14 |
| Stochastic Oscillator | 88.43 | 62.63 |
CS Disco Inc provides a cloud-native, artificial intelligence-powered legal solution that simplifies discovery, legal document review, and case management for enterprises, law firms, legal services providers, and governments. Its revenue-generating activities directly relate to the sale and support of legal solutions. It has two primary types of contractual arrangements: usage-based and subscription solutions. The usage-based revenue is derived from contracts under which customers are billed monthly based on their usage. Subscription revenue is derived from contracts where customers are contractually committed to a minimum data volume over a period of time.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on advancing novel genetic medicines. Its technology could provide a one-shot cure for a wide range of diseases that require strict, ongoing treatment regimens or have no effective treatment or only palliative care options. The Company is developing a silence-and-replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The company has a single operating segment, which is the business of discovery and development of therapeutic agents for the treatment of genetic disorders.